Breast Cancer

Adding atezolizumab to neoadjuvant chemotherapy did not significantly improve EFS in early TNBC, but node-positive and high-TIL subgroups showed benefit.

FDA approved camizestrant for HR+/HER2– advanced breast cancer with emerging ESR1 mutations based on data from the SERENA-6 trial.

Experts in breast cancer discussed final CAPItello-291 overall survival data and their implications for capivasertib plus fulvestrant.

Lisa Cassileth, MD, FACS, discussed her retrospective study showing that upsizing breast implants does not increase mastectomy flap necrosis risk.

Neil Iyengar, MD; Rebecca Shatsky, MD; and Carol Tweed, MD, discuss camizestrant and SERENA-6 ctDNA monitoring for ESR1-mutant HR+/HER2– breast cancer.

The European Commission has approved T-DXd plus pertuzumab as first-line therapy for HER2-positive metastatic breast cancer based on DESTINY-Breast09.

ASCO’s updated breast cancer follow-up guideline replaces routine, one-size-fits-all surveillance with a 3-tier, risk-based model.

Paxalisib produced a 100% clinical benefit rate and an 83% objective response rate in patients with metastatic triple-negative breast cancer.

The regulatory submission to expand the gedatolisib label to HR+/HER2-, PIK3CA-mutant advanced breast cancer is based on positive VIKTORIA-1 trial data.

Ami Shah, MD, Megan Kruse, MD, and Ruta Rao, MD, discuss DESTINY-Breast09, -11, and -05 data on trastuzumab deruxtecan in HER2-positive breast cancer.

The phase 2 Neo-CheckRay trial findings showed that adding durvalumab to radiation and chemotherapy nearly tripled pCR rates in PD-L1–negative ER+/HER2− breast cancer.

Gedatolisib plus fulvestrant, with or without palbociclib, now holds NCCN Category 1 status for HR+/HER2– PIK3CA wild-type advanced breast cancer.

Kay Yoon-Flannery, DO, MPH, FACS, discusses da Vinci Single Port robotic mastectomy, ranging from technique and patient selection to outcomes.

Kay Yoon-Flannery, DO, MPH, FACS, explained how the da Vinci Single Port 3D visualization improves precision vs open or multiport surgery.

Explore modern metastatic breast cancer care: longer survival, smarter symptom control, caregiver support, and steps to close racial treatment gaps.

Kathryn Eckert, DO, spoke about diversifying breast imaging technology after the Hologic Brevera needle recall.

Kathryn Eckert, DO, shared how her team communicates with patients and keeps referral guidelines unchanged during the shortage.

Kathryn Eckert, DO, discussed her role of bridging surgery and radiology teams as breast biopsy needle shortages continue nationwide.

Kathryn Eckert, DO, described how her breast surgery practice and imaging partners responded on day 1 of the Hologic Brevera needle recall.

A breast surgeon and a radiologist describe the impact the breast biopsy needle shortage has had on their current clinical practice.

In 50,845 SEER patients aged ≥70 years with stage I ER-positive breast cancer after BCS, radiation omission was not associated with inferior BCSS (aHR, 0.95; 95% CI, 0.87-1.04), though radiation conferred modest OS benefit, supporting selective de-escalation in older patients.

Sara Hurvitz, MD, FACP, explained how to prevent and manage stomatitis in patients with breast cancer receiving the newly approved gedatolisib.

In a prospective pilot of 74 patients enriched for under-represented risk factors, 15-fraction breast/chest wall RT with SIB yielded 10-year LRFS of 93.1%, DMFS of 94.2%, and OS of 89.2%, with no grade 3 brachial plexopathy or significant lymphedema, supporting condensed SIB use in routine practice.

In 536,783 NCDB breast RT courses from 2020 to 2023, 5-fraction RT rose from 4.3% to 17.4% overall, with uptake significantly lower among uninsured patients (6.9%), Black patients (9.4% vs 12.2% White), and mid-size metro areas, revealing persistent access disparities.

Dosing has resumed in the INVINCIBLE-4 trial of INT230-6 plus standard therapy in early-stage triple-negative breast cancer.